SCHEDULE 13G/A: Soleus Capital Master Fund Reaffirms 9.6% Passive Stake in Terns Pharmaceuticals
Beneficial Ownership Disclosure
Soleus Capital Master Fund, L.P. and its affiliated entities have filed an amended Schedule 13G, reaffirming their passive beneficial ownership of 9.6% of Terns Pharmaceuticals, Inc.'s common stock as of December 31, 2024.
Summary
- Soleus Capital Master Fund, L.P., along with its related entities (Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy), collectively reported beneficial ownership of 8,142,500 shares of Terns Pharmaceuticals, Inc. common stock.
- This ownership represents 9.6% of the Issuer's outstanding common stock.
- The percentage is calculated based on 84,938,855 shares of Terns Pharmaceuticals, Inc. common stock outstanding as of November 8, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q.
- The filing indicates that the shares are held for investment purposes and not with the intent to change or influence the control of the Issuer.
- All reporting persons share both voting and dispositive power over the 8,142,500 shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the issuer's performance or prospects. It is a neutral, compliance-driven filing.
Positives
- The disclosure of a significant institutional investor like Soleus Capital holding a substantial stake (9.6%) can be viewed as a positive signal, indicating confidence in the company's long-term prospects from a sophisticated investor.
Risks
- This filing itself does not introduce new risks for Terns Pharmaceuticals, Inc. It is a routine disclosure of a passive investment stake.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Terns Pharmaceuticals, Inc.'s future outlook.
Industry Context
This filing is a routine disclosure of a passive investment stake by an institutional investor in a publicly traded pharmaceutical company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact that Terns Pharmaceuticals, Inc. is a company attracting institutional investment.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming a large, passive investment.
Key Dates
| Date | Description |
|---|---|
| 2024-11-08 | Date as of which 84,938,855 shares of Terns Pharmaceuticals, Inc. common stock were reported outstanding in the Issuer's Form 10-Q. |
| 2024-12-31 | Date of event which requires the filing of this statement (reporting date for beneficial ownership). |
| 2025-02-11 | Date of filing and signature by reporting persons. |
Keywords
Terns Pharmaceuticals, Soleus Capital Master Fund, Schedule 13G, Beneficial Ownership, Passive Investment, SEC Filing, Common Stock, Institutional Investor, 880881107
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.